Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Blood (2022) 140 (Supplement 1): 1716–1719.

https://doi.org/10.1182/blood-2022-157326

Published: 2022

Journal Articles

5hmC Gene Signature Predicts the Treatment Response to Azacitidine with High-Dose Cytarabine and Mitoxantrone in AML

Kirk Cahill, Linchen Wang, Guanghao Liang, Qiancheng You, Chuanyuan Chen, Wei Zhang, Noreen Fulton, Wendy Stock, Olatoyosi Odenike, Chuan He, Dali Han

Blood (2021) 138 (Supplement 1): 1305.

https://doi.org/10.1182/blood-2021-151951

Published: 2021

Journal Articles

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Blood (2019) 133 (14): 1548–1559.

https://doi.org/10.1182/blood-2018-10-881961

Published: 2019

Includes: Supplemental data

Journal Articles

Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)

Lawrence D Kaplan, MD, Matthew J. Maurer, MS, Wendy Stock, MD, Nancy L. Bartlett, MD, Noreen Fulton, BS, Adam Pettinger, John C. Byrd, MD, Kristie A. Blum, MD, Ann S. LaCasce, MD MSc, David Duane Hurd, MD, Amy S. Ruppert, MAS, PhD, Francisco J. Hernandez-Ilizaliturri, MD, John P. Leonard, MD, Bruce Cheson, MD

Blood (2018) 132 (Supplement 1): 146.

https://doi.org/10.1182/blood-2018-99-112655

Published: 2018

Journal Articles

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Kothari Shawn, MD, Andrew Artz, MD, Sang Mee Lee, PhD, Noreen Fulton, BS, Jae-Hyun Park, Wendy Stock, MD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Justin Kline, MD, Lucy Godley, MD PhD, James LaBelle, MD PhD, Satyajit Kosuri, MD, Peter A Riedell, MD, Yusuke Nakamura, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2017) 130 (Supplement 1): 4572.

https://doi.org/10.1182/blood.V130.Suppl_1.4572.4572

Published: 2017

Journal Articles

Inhibition of FLT3-ITD and Melk By Small Molecule Inhibitor OTS167 in FLT3 mutant Acute Myeloid Leukemia (AML)

Bartholomew Eisfelder, PhD, Houda Alachkar, PharmD, PhD, Margaret Colton, Noreen Fulton, BS, Olatoyosi Odenike, MD, Yusuke Nakamura, MD, Wendy Stock, MD

Blood (2017) 130 (Supplement 1): 2525.

https://doi.org/10.1182/blood.V130.Suppl_1.2525.2525

Published: 2017

Journal Articles

WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia

Hongtao Liu, MD PhD, Yuanyuan Zha, PhD, Gregory Malnassy, Noreen Fulton, Margaret Green, Jae-Hyun Park, PhD, Yusuke Nakamura, MD, Richard A. Larson, MD, Andres M Salazar, Olatoyosi Odenike, MD, Thomas Gajewski, MD PhD, Wendy Stock, MD

Blood (2016) 128 (22): 3984.

https://doi.org/10.1182/blood.V128.22.3984.3984

Published: 2016

Journal Articles

TCR Clonal Evolution in AML Patients in Morphologic Remission Treated with Anti-PD1 Antibody, Nivolumab

Hongtao Liu, MD PhD, Jae-Hyun Park, PhD, Noreen Fulton, Kazuma Kiyotani, PhD, Yusuke Nakamura, MD, Olatoyosi Odenike, MD, Wendy Stock, MD

Blood (2016) 128 (22): 2325.

https://doi.org/10.1182/blood.V128.22.2325.2325

Published: 2016

Journal Articles

Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)

Yasmin H Karimi, MD, Nitin Jain, MD, Margaret Green, Lucy A Godley, MD, PhD, Howie Lawrence Weiner, Gregory Malnassy, Noreen Fulton, Andrew Artz, MD MS, Hongtao Liu, MDPhD, Michael J. Thirman, MD, Michael Daunov, Richard A. Larson, MD, Wendy Stock, MD, Olatoyosi Odenike, MD

Blood (2015) 126 (23): 3777.

https://doi.org/10.1182/blood.V126.23.3777.3777

Published: 2015

Journal Articles

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

Lawrence D. Kaplan, MD, Sin-Ho Jung, PhD, Wendy Stock, MD, Nancy L. Bartlett, MD, Brandelyn Pitcher, MS, John C. Byrd, MD, Kristie A. Blum, MD, Ann S. LaCasce, MD, Noreen Fulton, Eric D. Hsi, MD, David D Hurd, MD, Myron Czuczman, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 337.

https://doi.org/10.1182/blood.V126.23.337.337

Published: 2015

Journal Articles

Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance)

Greg Malnassy, MS, Susan Geyer, PhD, Noreen Fulton, B.S., Greg Koval, B.S., Donna Niedzwiecki, PhD, Victoria Carlton, PhD, Li Weng, PhD, Lawrence D. Kaplan, MD, Guido Marcucci, MD, Lloyd E Damon, MD, Richard A. Larson, MD, Richard M. Stone, MD, Bruce D. Cheson, M.D., Malek Faham, MD, PhD, Wendy Stock, M.D.

Blood (2013) 122 (21): 2547.

https://doi.org/10.1182/blood.V122.21.2547.2547

Published: 2013

Journal Articles

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Noreen Fulton, B.S., Jeffrey Johnson, M.S., Lawrence D. Kaplan, M.D., Greg Koval, B.S., Greg Malnassy, B.S., Sin-Ho Jung, Ph.D., Steve Devine, M.D., Thomas C. Shea, M.D., John P. Leonard, M.D., Bruce D. Cheson, M.D., Wendy Stock, M.D.

Blood (2013) 122 (21): 3002.

https://doi.org/10.1182/blood.V122.21.3002.3002

Published: 2013

Journal Articles

Novel transcription factors in human CD34 antigen–positive hematopoietic cells

Ignatius Gomes, Tiffany T. Sharma, Seby Edassery, Noreen Fulton, Brenton G. Mar, Carol A. Westbrook

Blood (2002) 100 (1): 107–119.

https://doi.org/10.1182/blood.V100.1.107

Published: 2002

Journal Articles

Highly abundant genes in the transcriptosome of human and baboon CD34 antigen-positive bone marrow cells

Ignatius Gomes, Tiffany T. Sharma, Nadim Mahmud, Jeffrey D. Kapp, Seby Edassery, Noreen Fulton, Jie Liang, Ronald Hoffman, Carol A. Westbrook

Blood (2001) 98 (1): 93–99.

https://doi.org/10.1182/blood.V98.1.93

Published: 2001

Includes: Supplemental data

NARROW

Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

5hmC Gene Signature Predicts the Treatment Response to Azacitidine with High-Dose Cytarabine and Mitoxantrone in AML

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Inhibition of FLT3-ITD and Melk By Small Molecule Inhibitor OTS167 in FLT3 mutant Acute Myeloid Leukemia (AML)

WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia

TCR Clonal Evolution in AML Patients in Morphologic Remission Treated with Anti-PD1 Antibody, Nivolumab

Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance)

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Novel transcription factors in human CD34 antigen–positive hematopoietic cells

Highly abundant genes in the transcriptosome of human and baboon CD34 antigen-positive bone marrow cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only